BioSpace News Archive

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced a new multi-indication gastrointestinal (GI) cancer study to be managed by AIO, a leading academic cooperative medical oncology group based in Germany.

Moleculin Biotech, Inc. announced that members of management will participate in a panel at ROTH Capital’s healthcare event titled, “COVID-19 Therapeutics in Development,” taking place on Wednesday, October 28th, 2020.

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, and Catapult Health, the leading national provider of employer-sponsored Preventive Checkups, have formed a collaboration designed to help organizations facilitate virtual (telehealth) access to clinical services for their employees and adult dependents,

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its third quarter 2020 financial results will be released after the market closes on Thursday, November 5, 2020.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced the Company will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2020 financial results on Thursday, October 29, 2020 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT) that day to discuss the financial results and to provide a clinical update.

Datavant, the leader in helping healthcare organizations safely connect and exchange their data, and Castor, a leading provider of clinical trial technology, today announced a partnership designed to increase clinical trial efficiency and enable life sciences companies and CROs to more efficiently use real-world data.

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced the first patient has been dosed in the Phase 2 expansion portion of the study evaluating DSP-7888, an investigational immunotherapeutic cancer vaccine that targets Wilms Tumor 1 (WT1),

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary aesthetic platform technology, today announced it has appointed Michael S. Kaminer, M.D. to Soliton’s Board of Directors.

- Oral presentation will highlight the potent anti-tumor effects demonstrated by TJ210, a novel antibody that blocks C5aR by binding to a unique epitope